Haleon plc (LON:HLN - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 431.82 ($5.57) and last traded at GBX 394.10 ($5.08), with a volume of 65438391 shares changing hands. The stock had previously closed at GBX 388.20 ($5.00).
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank raised their target price on shares of Haleon from GBX 456 ($5.88) to GBX 457 ($5.89) and gave the company a "buy" rating in a research report on Friday, February 28th.
View Our Latest Analysis on Haleon
Haleon Price Performance
The business's 50 day simple moving average is GBX 388.98 and its 200-day simple moving average is GBX 381.69. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a market capitalization of £35.83 billion, a price-to-earnings ratio of 33.39, a P/E/G ratio of 1.49 and a beta of 0.19.
Haleon (LON:HLN - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. On average, research analysts forecast that Haleon plc will post 19.5033282 earnings per share for the current year.
Haleon Increases Dividend
The firm also recently disclosed a dividend, which will be paid on Thursday, June 5th. Stockholders of record on Thursday, April 24th will be paid a GBX 4.60 ($0.06) dividend. This represents a dividend yield of 1.18%. This is an increase from Haleon's previous dividend of $2.00. The ex-dividend date of this dividend is Thursday, April 24th. Haleon's payout ratio is currently 50.46%.
Haleon Company Profile
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.
Further Reading
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
